BridgeMD
Tests treatment safety and results for Advanced NSCLC
Official title Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
ClinicalTrials.gov ID: NCT06924606
What this study is testing
What is JS207 injection +docetaxel?
JS207 injection +docetaxel is an investigational medicine, being studied as a potential treatment for advanced nsclc.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC that is not amenable to radical surgery or radical...
- people with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combined...
- people must have at least one measurable lesion according to RECIST v1.1.
You likely can't join if
- Histopathologically or cytopathologically confirmed to have combined neuroendocrine component.
- Sensitivity mutation of EGFR or ALK fusion.
- Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Jilin City, Changchun, China
- Hunan, Changsha, China
- Sichuan, Chengdu, China
- Chongqing, Chongqing Municipality, China
- Guangdong, Guangzhou, China
- Heilongjiang, Harbin, China
- Anyang, Henan, China
- Luoyang, Henan, China
- Xinxiang, Henan, China
- Changde, Hunan, China
- Jiangxi, Nanchang, China
- Shanghai, Shanghai Municipality, China
- Datong, Shanxi, China
- Yibin, Sichuan, China
- Xinjiang, Xinjiang, China
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Jilin City, Changchun, China; Hunan, Changsha, China; Sichuan, Chengdu, China; Chongqing, Chongqing Municipality, China; Guangdong, Guangzhou, China and 11 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.